THE INVESTOR

메뉴열기
December 17, 2018
[THE INVESTOR] The Korean market operator’s decision to delist a local pharmaceuticals company is raising questions about the fairness in authorities’ action against firms accused of accounting errors, with investors comparing the case to that of Samsung BioLogics. A panel led by the Korea Exchange, the nation’s sole market operator, suggested Dec. 14 the removal of Kyung Nam Pharm, a Seoul-headquartered pharmaceutical company, from the second-tier Kosdaq market, putting the fate of the company
  • KOSPI 2068.70 ▼-0.68
  • KOSDAQ 657.59 ▼-8.75
  • USD/KRW 1112.88 ▼-1.77
  • CNH/KRW 155.90 ▼-0.22
  • DUBAI 449529.1
  • TB(3Year) 1.781
이전 다음
최상단으로
Herald Corporation|CEO : Kwon Chung Won
Chief Privacy Officer & Juvenile Protection Manager : Shin Chang Hoon
Company Registration No. 104-81-06004
Mail-Order Business Registration 2016 - Seoul Yongsan - 00590
Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea
T : +82-2-727-0615|Business info
COPYRIGHT HERALD CORPORATION. ALL RIGHTS RESERVED.